Publications by authors named "Susanna Esteba"
Article Synopsis
- Despite numerous clinical trials, there is currently no effective pharmacological treatment for Fragile-X syndrome (FXS), prompting the exploration of epigallocatechin-3-gallate (EGCG) as a potential therapy.
- Preclinical studies in Fmr1 knockout mice indicated that EGCG can enhance memory, and a phase I clinical trial showed that FXS patients treated with EGCG plus cognitive training experienced significant cognitive improvements compared to those on a placebo.
- The findings suggest that further phase 2 clinical trials with larger participant groups are needed to confirm EGCG's effectiveness in improving cognition and daily functioning for individuals with FXS.
